Moderna (NASDAQ:MRNA) Releases Earnings Results, Beats Estimates By $0.52 EPS

Moderna (NASDAQ:MRNA) issued its quarterly earnings results on Thursday. The company reported ($3.07) EPS for the quarter, beating analysts’ consensus estimates of ($3.59) by $0.52, Briefing.com reports. The company had revenue of $167.00 million for the quarter, compared to analyst estimates of $93.26 million. Moderna had a negative return on equity of 20.10% and a negative net margin of 115.82%. The company’s quarterly revenue was down 91.0% compared to the same quarter last year. During the same period last year, the company earned $0.19 earnings per share.

Moderna Price Performance

MRNA traded down $0.59 during trading on Friday, reaching $125.00. The company had a trading volume of 4,513,133 shares, compared to its average volume of 3,445,723. The firm’s 50-day simple moving average is $105.05 and its 200 day simple moving average is $94.37. Moderna has a 12-month low of $62.55 and a 12-month high of $142.79. The company has a current ratio of 4.03, a quick ratio of 3.36 and a debt-to-equity ratio of 0.04.

Analysts Set New Price Targets

MRNA has been the topic of a number of research analyst reports. Oppenheimer raised their price target on Moderna from $142.00 to $163.00 and gave the company an “outperform” rating in a report on Friday. Canaccord Genuity Group raised their price target on Moderna from $91.00 to $106.00 and gave the company a “hold” rating in a report on Friday. Royal Bank of Canada raised their price target on Moderna from $125.00 to $135.00 and gave the company an “outperform” rating in a report on Friday. William Blair reaffirmed a “market perform” rating on shares of Moderna in a report on Monday, April 1st. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a report on Thursday. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, Moderna currently has a consensus rating of “Hold” and an average price target of $129.55.

Insider Buying and Selling

In related news, insider Shannon Thyme Klinger sold 670 shares of Moderna stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $94.57, for a total value of $63,361.90. Following the transaction, the insider now owns 8,557 shares of the company’s stock, valued at approximately $809,235.49. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Moderna news, President Stephen Hoge sold 2,388 shares of the firm’s stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $225,833.16. Following the completion of the sale, the president now directly owns 1,515,898 shares in the company, valued at approximately $143,358,473.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Shannon Thyme Klinger sold 670 shares of the firm’s stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $94.57, for a total value of $63,361.90. Following the sale, the insider now owns 8,557 shares of the company’s stock, valued at $809,235.49. The disclosure for this sale can be found here. In the last quarter, insiders have sold 139,954 shares of company stock valued at $14,822,576. 15.70% of the stock is owned by corporate insiders.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.